Literature DB >> 2671327

Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism.

C Restrepo de Rovetto1, T R Welch, G Hug, K E Clark, W Bergstrom.   

Abstract

Some children with Bartter syndrome have hypercalciuria. To determine the mechanism for this phenomenon, we studied tubular function and calcium metabolism in six such children. All patients had hypokalemic alkalosis, normotension, hyperreninemia, growth retardation, low fractional distal chloride reabsorption (4/5), and elevated urinary prostaglandin E2 excretion (5/6). In addition, all had hypercalciuria (urinary calcium 6.5 to 25.0 mg/kg/day), with evidence of nephrocalcinosis in five. None, however, had evidence of rickets or hyperparathyroidism. There was a marked elevation in the serum concentration of 1,25-dihydroxyvitamin D in all, and four patients had a response to oral calcium loading suggestive of absorptive hypercalciuria. Five children have had long-term therapy with indomethacin. They have had improvement in hypokalemia and reduced urinary prostaglandin E2 excretion as well as reductions in the serum concentration of 1,25-dihydroxyvitamin D and in urinary calcium excretion. These data suggest that hypercalciuria in some children with Bartter syndrome is associated with an excess of 1,25-dihydroxyvitamin D. The improvement in hypercalciuria with prostaglandin synthesis inhibition may result in part from correction of this vitamin D abnormality.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2671327     DOI: 10.1016/s0022-3476(89)80838-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Understanding Bartter syndrome and Gitelman syndrome.

Authors:  Oliver T Fremont; James C M Chan
Journal:  World J Pediatr       Date:  2012-01-27       Impact factor: 2.764

2.  Bone mineral density and bone turnover in patients with Bartter syndrome.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Mireia Aguirre
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

3.  Pre-pubertal growth in the hyperprostaglandin E syndrome.

Authors:  C Seidel; S Reinalter; H W Seyberth; K Schärer
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

4.  A novel compound heterozygous ROMK mutation presenting as late onset Bartter syndrome associated with nephrocalcinosis and elevated 1,25(OH)(2) vitamin D levels.

Authors:  Amita Sharma; Micheal A Linshaw
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

Review 5.  Prostanoids in paediatric kidney diseases.

Authors:  H W Seyberth; A Leonhardt; B Tönshoff; N Gordjani
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

6.  Angiotensin II reduces calcium uptake into bone.

Authors:  Scott J Schurman; William H Bergstrom; Lawrence R Shoemaker; Thomas R Welch
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

7.  Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome.

Authors:  Thomas R Welch; David R Shaffer; Darren R Feldman
Journal:  Case Rep Nephrol Dial       Date:  2017-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.